Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel-Reference-Cited by-同舟云学术

Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel

Published:2018-08 Issue:4 Volume:16 Page:318-324
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Buttigliero Consuelo^ORCID,Tucci Marcello,Vignani Francesca,Di Stefano Rosario F.,Leone Gianmarco,Zichi Clizia^ORCID,Pignataro Daniele,Lacidogna Gaetano,Guglielmini Pamela,Numico Gianmauro,Scagliotti Giorgio V.,Di Maio Massimo^ORCID

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference38 articles.

1. Cancer statistics, 2017;Siegel;CA Cancer J Clin,2017

2. Endocrine control of prostatic cancer;Huggins;Science,1943

3. EAU-ESTRO-SIOG guidelines on prostate cancer. part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer;Cornford;Eur Urol,2017

4. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

5. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;de Bono;Lancet,2010

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Icariin as a potential anticancer agent: a review of its biological effects on various cancers;Frontiers in Pharmacology;2023-06-30

2. PD-L1 Inhibitors for the Treatment of Prostate Cancer;Current Drug Targets;2020-11-27

3. Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer;Scientific Reports;2020-11-06

4. Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer;Anticancer Research;2020-07-29

5. Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis;Clinical Genitourinary Cancer;2019-08